Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Chromosome 18 Clinical Research Center

NCT00227253 · View on ClinicalTrials.gov ↗

Study Summary

Our vision, that of the researchers at the University of Texas Health Science Center at San Antonio, is that every person with a chromosome 18 abnormality will have an autonomous and healthy life. Our mission is to provide families affected by chromosome 18 abnormalities with comprehensive medical and educational information. Our goals are to provide definitive medical and education resources for the families of individuals with chromosome 18 abnormalities; perform and facilitate groundbreaking clinical and basic research relating to the syndromes of chromosome 18; and to provide treatments to help these individuals overcome the effects of their chromosome abnormality.

Interventions

  • PROCEDURE Determination of growth hormone status
  • PROCEDURE Measurement of growth, thyroid and sex hormone levels
  • PROCEDURE Behavior and neuropsychometric evaluations
  • PROCEDURE Audiological and ear, nose and throat examination
  • PROCEDURE Magnetic resonance imaging of the brain

Study Locations (2)

Texas

  • University Health Systems Hospital — San Antonio
  • University of Texas Health Science Center at San Antonio — San Antonio

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 1993-09
Est. Completion 2040-12

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00227253

The ClinicalTrials.gov registry entry for NCT00227253 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 481 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 5 interventions — of which Determination of growth hormone status is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00227253 reports 2 study locations spanning 1 distinct geographic area — top geographies include Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00227253 about?

NCT00227253 is a clinical study titled "Chromosome 18 Clinical Research Center". Our vision, that of the researchers at the University of Texas Health Science Center at San Antonio, is that every person with a chromosome 18 abnormality will have an autonomous and healthy life. Our mission is to provide families affected by chromosome 18 abnormalities with comprehensive medical a...

What is the current status of trial NCT00227253?

This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 1993-09. Estimated completion is 2040-12.

What conditions does trial NCT00227253 study?

This clinical trial studies the following conditions: Growth Hormone Deficiency, Chromosome Aberrations, Hypomyelination. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00227253?

The interventions under investigation include: Determination of growth hormone status (PROCEDURE), Measurement of growth, thyroid and sex hormone levels (PROCEDURE), Behavior and neuropsychometric evaluations (PROCEDURE), Audiological and ear, nose and throat examination (PROCEDURE), Magnetic resonance imaging of the brain (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00227253?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 481 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00227253 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial